These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 3276360)
1. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Storb R; Deeg HJ; Fisher L; Appelbaum F; Buckner CD; Bensinger W; Clift R; Doney K; Irle C; McGuffin R Blood; 1988 Feb; 71(2):293-8. PubMed ID: 3276360 [TBL] [Abstract][Full Text] [Related]
2. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Storb R; Deeg HJ; Pepe M; Appelbaum F; Anasetti C; Beatty P; Bensinger W; Berenson R; Buckner CD; Clift R Blood; 1989 May; 73(6):1729-34. PubMed ID: 2653461 [TBL] [Abstract][Full Text] [Related]
3. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012 [TBL] [Abstract][Full Text] [Related]
4. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Storb R; Pepe M; Anasetti C; Appelbaum FR; Beatty P; Doney K; Martin P; Stewart P; Sullivan KM; Witherspoon R Blood; 1990 Sep; 76(5):1037-45. PubMed ID: 2203481 [TBL] [Abstract][Full Text] [Related]
5. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Deeg HJ; Storb R; Thomas ED; Flournoy N; Kennedy MS; Banaji M; Appelbaum FR; Bensinger WI; Buckner CD; Clift RA Blood; 1985 Jun; 65(6):1325-34. PubMed ID: 3888312 [TBL] [Abstract][Full Text] [Related]
6. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Storb R; Deeg HJ; Thomas ED; Appelbaum FR; Buckner CD; Cheever MA; Clift RA; Doney KC; Flournoy N; Kennedy MS Blood; 1985 Sep; 66(3):698-702. PubMed ID: 2862933 [TBL] [Abstract][Full Text] [Related]
7. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Ringdén O; Horowitz MM; Sondel P; Gale RP; Biggs JC; Champlin RE; Deeg HJ; Dicke K; Masaoka T; Powles RL Blood; 1993 Feb; 81(4):1094-101. PubMed ID: 8427991 [TBL] [Abstract][Full Text] [Related]
8. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058 [TBL] [Abstract][Full Text] [Related]
9. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Storb R; Deeg HJ; Farewell V; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J Blood; 1986 Jul; 68(1):119-25. PubMed ID: 3521761 [TBL] [Abstract][Full Text] [Related]
10. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942 [No Abstract] [Full Text] [Related]
11. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Storb R; Deeg HJ; Pepe M; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J Br J Haematol; 1989 Aug; 72(4):567-72. PubMed ID: 2673331 [TBL] [Abstract][Full Text] [Related]
12. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768 [TBL] [Abstract][Full Text] [Related]
13. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Morishima Y; Morishita Y; Tanimoto M; Ohno R; Saito H; Horibe K; Hamajima N; Naito K; Yamada K; Yokomaku S Blood; 1989 Nov; 74(6):2252-6. PubMed ID: 2804362 [TBL] [Abstract][Full Text] [Related]
14. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846 [TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J; Ringdén O Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [TBL] [Abstract][Full Text] [Related]
16. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Ruutu T; Volin L; Parkkali T; Juvonen E; Elonen E Blood; 2000 Oct; 96(7):2391-8. PubMed ID: 11001889 [TBL] [Abstract][Full Text] [Related]
17. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Sullivan KM; Deeg HJ; Sanders J; Klosterman A; Amos D; Shulman H; Sale G; Martin P; Witherspoon R; Appelbaum F Blood; 1986 Apr; 67(4):1172-5. PubMed ID: 3513869 [TBL] [Abstract][Full Text] [Related]
18. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Aschan J; Ringdén O; Sundberg B; Gahrton G; Ljungman P; Winiarski J Bone Marrow Transplant; 1991 Feb; 7(2):113-9. PubMed ID: 2049554 [TBL] [Abstract][Full Text] [Related]
19. Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. Irle C; Deeg HJ; Buckner CD; Kennedy M; Clift R; Storb R; Appelbaum FR; Beatty P; Bensinger W; Doney K Leuk Res; 1985; 9(10):1255-61. PubMed ID: 3906282 [TBL] [Abstract][Full Text] [Related]
20. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Doney K; Fisher LD; Appelbaum FR; Buckner CD; Storb R; Singer J; Fefer A; Anasetti C; Beatty P; Bensinger W Bone Marrow Transplant; 1991 Jun; 7(6):453-9. PubMed ID: 1873592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]